Advertisement

MAO-B inhibition in rabbit tissues and in human platelets by Ro 19-6327 shows similar time-course

  • R. Kettler
  • A. M. Cesura
  • J. Dingemanse
  • M. Da Prada
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)

Summary

In rabbits, 3mg/kg Ro 19-6327 p.o., induced complete monoamine oxidase type B (MAO-B) inhibition in striatum, cerebral cortex, liver and platelets for about 12 h. In healthy human volunteers complete inhibition of platelet MAO was obtained with only 5 mg Ro 19-6327. After 40 and 200 mg Ro 19-6327 the duration of complete MAO-B inhibition was prolonged to 12 and 24 hours, respectively. Changes in brain MAO-B in humans after Ro 19-6327 are likely to be faithfully reflected by platelet MAO activity.

Keywords

Frontal Cortex Blood Platelet Healthy Human Volunteer Rabbit Tissue Monoamine Oxidase Type 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Da Prada M, Kettler R, Keller HH, Burkard WP (1988) Ro 19-6327, a reversible, highly selective inhibitor of type B monoamine oxidase, completely devoid of tyramine-potentiating effects: comparison with selegiline. In: Sandler M, Dahlström A, Belmaker RH (eds) Progress in catecholamine research, part B. Central aspects. Alan R Liss, New York, pp 359–363.Google Scholar
  2. Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248:400–414.PubMedGoogle Scholar
  3. Kettler R, Da Prada M (1989) Platelet MAO-B activity in humans and stumptail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro 19-6327. In: Przuntek H, Riederer P (eds) Early diagnosis and preventive therapy in Parkinson’s disease. Springer, Wien New York, pp 213–219.CrossRefGoogle Scholar
  4. Oreland L, Johanson F, Ekstedt J (1983) Dose regimen of deprenyl (selegiline) and platelet MAO activities. Acta Neurol Scand [Suppl] 95:87–89.CrossRefGoogle Scholar
  5. Price GW, Bench CJ, Cremer JC, Luthra SK, Turton DR, Lammertsma AA, Kettler R, Da Prada M, Wood N, Jamieson V, McClelland G, Frackowiak RSJ (1990) Inhibition of human brain monoamine oxidase-B by Ro 19-6327 — in vivo measurement using positron emission tomography. Eur J Pharmacol 183: 166.CrossRefGoogle Scholar
  6. Riederer P, Youdim MBH, Rausch WD, Birkmayer W, Jellinger K, Seemann D (1978) On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm 43:217–226.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • R. Kettler
    • 1
  • A. M. Cesura
    • 1
  • J. Dingemanse
    • 2
  • M. Da Prada
    • 1
  1. 1.Pharmaceutical Research DepartmentF. Hoffmann-La Roche LtdBaselSwitzerland
  2. 2.Clinical Research DepartmentsF. Hoffmann-La Roche LtdBaselSwitzerland

Personalised recommendations